Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanSino BiologicsCASBF 69 PB Ratio is 0.91 as of Jul. 15, 2026, which is 32% below its 10-year median of 1.33. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.73 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, CanSino Biologics ranks better than 72.23% on this metric.
The historical rank and industry rank for CanSino Biologics's PB Ratio or its related term are showing as below:
CASBF'
s PB Ratio Range Over the Past 10 Years
Min: 0.68 Med: 1.33 Max: 2.57
Current: 1.06
During the past 10 years, CanSino Biologics's highest PB Ratio was 2.57. The lowest was 0.68. And the median was 1.33.
CASBF's PB Ratio is ranked better than 72.23% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.92
vs CASBF: 1.06
During the past 12 months, CanSino Biologics's average Book Value Per Share Growth Rate was 4.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.50% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of CanSino Biologics was 147.30% per year. The lowest was -18.80% per year. And the median was 60.60% per year.
Back to Basics: PB Ratio
CanSino Biologics (OTCPK:CASBF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CanSino Biologics PB Ratio Related Terms
CanSino Biologics PB Ratio Historical Data
* Premium members only.
The historical data trend for CanSino Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanSino Biologics PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where CanSino Biologics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CanSino Biologics (CASBF) has a PB Ratio of 0.91 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CanSino Biologics and its competitors. This is 32% below median its historical median of 1.33. Over the past decade, CanSino Biologics' PB Ratio has ranged from 0.68 to 2.57. According to the industry distribution chart, CanSino Biologics ranks #256 out of 922 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is CanSino Biologics' PB Ratio too high?
CanSino Biologics' current PB Ratio of 0.91 is 32% below median its 10-year median of 1.33. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 2.57. The Drug Manufacturers industry median PB Ratio is 1.92. CanSino Biologics' value of 0.91 is 52.6% below this industry median. Based on the distribution chart, CanSino Biologics ranks #256 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, CanSino Biologics ranks #256 out of 922 companies for PB Ratio. This puts CanSino Biologics in the upper half of its industry. The industry median PB Ratio is 1.92. CanSino Biologics' value of 0.91 is 52.6% below this benchmark. Historically, CanSino Biologics' own PB Ratio has ranged from 0.68 to 2.57 over the past decade. While the company's 10-year median is 1.33 vs. the industry median of 1.92, CanSino Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.92, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanSino Biologics's current PB Ratio of 0.91 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CanSino Biologics and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanSino Biologics's current PB Ratio is 0.91, which is 32% below median its own 10-year median of 1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.73, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current PB Ratio is 0.91, which is 32% below median its 10-year median of 1.33 and 52.6% below the Drug Manufacturers industry median of 1.92. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current PB Ratio is 0.91 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CanSino Biologics (CASBF) Overvalued in 2026?
Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued.
The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.73.
GuruFocus considers CanSino Biologics to be Significantly Undervalued.
Key valuation signals for CASBF:
PB Ratio: 0.91 (32% below median its 10-year median of 1.33)
GF Value™: $8.73 vs. price of $2.60 (70.2% below fair value)
Industry Position: 52.6% below the Drug Manufacturers median (#256 of 922)
No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score
Get the complete analysis for CASBF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CASBF has been successfully added to your 
